Mitsuru Shinohara

Dr. Mitsuru Shinohara

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2020 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
ZLZonghua Li
Zonghua Li
FSFrancis Shue
Francis Shue
NZNa Zhao
Na Zhao
MSMitsuru Shinohara
Mitsuru Shinohara
GBGuojun Bu
Guojun Bu
Investigations of apolipoprotein E (APOE) gene, the major genetic risk modifier for Alzheimer’s disease (AD), have yielded significant insights into the pathogenic mechanism. Among the three common coding variants,APOE*ε4increases, whereasAPOE*ε2decreases the risk of late-onset AD compared withAPOE*ε3. Despite increased understanding of the detrimental effect ofAPOE*ε4, it remains unclear howAPOE*ε2confers protection against AD. Accumulating evidence suggests thatAPOE*ε2protects against AD through both amyloid-β (Aβ)-dependent and independent mechanisms. In addition,APOE*ε2has been identified as a longevity gene, suggesting a systemic effect ofAPOE*ε2on the aging process. However,APOE*ε2is not entirely benign;APOE*ε2carriers exhibit increased risk of certain cerebrovascular diseases and neurological disorders. Here, we review evidence from both human and animal studies demonstrating the protective effect ofAPOE*ε2against AD and propose a working model depicting potential underlying mechanisms. Finally, we discuss potential therapeutic strategies designed to leverage the protective effect ofAPOE2to treat AD.

1 July 2017 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
MSMitsuru Shinohara
Mitsuru Shinohara
MTMASAYA TACHIBANA
MASAYA TACHIBANA
TKTakahisa Kanekiyo
Takahisa Kanekiyo
GBGuojun Bu
Guojun Bu
Among the LDL receptor (LDLR) family members, the roles of LDLR-related protein (LRP)1 in the pathogenesis of Alzheimer’s disease (AD), especially late-onset AD, have been the most studied by genetic, neuropathological, and biomarker analyses (clinical studies) or cellular and animal model systems (preclinical studies) over the last 25 years. Although there are some conflicting reports, accumulating evidence from preclinical studies indicates that LRP1 not only regulates the metabolism of amyloid-β peptides (Aβs) in the brain and periphery, but also maintains brain homeostasis, impairment of which likely contributes to AD development in Aβ-independent manners. Several preclinical studies have also demonstrated an involvement of LRP1 in regulating the pathogenic role of apoE, whose gene is the strongest genetic risk factor for AD. Nonetheless, evidence from clinical studies is not sufficient to conclude how LRP1 contributes to AD development. Thus, despite very promising results from preclinical studies, the role of LRP1 in AD pathogenesis remains to be further clarified. In this review, we discuss the potential mechanisms underlying how LRP1 affects AD pathogenesis through Aβ-dependent and -independent pathways by reviewing both clinical and preclinical studies. We also discuss potential therapeutic strategies for AD by targeting LRP1.

19 October 2020 in eLife
Verified
Journal Article
Open access
MSMitsuru Shinohara
Mitsuru Shinohara
TKTakahisa Kanekiyo
Takahisa Kanekiyo
MTMasaya Tachibana
Masaya Tachibana
AKAishe Kurti
Aishe Kurti
MSMotoko Shinohara
Motoko Shinohara
GBGuojun Bu
Guojun Bu
Although the ε2 allele of apolipoprotein E (APOE2) benefits longevity, its mechanism is not understood. The protective effects of theAPOE2 on Alzheimer’s disease (AD) risk, particularly through their effects on amyloid or tau accumulation, may confoundAPOE2effects on longevity. Herein, we showed that the association betweenAPOE2and longer lifespan persisted irrespective of AD status, including its neuropathology, by analyzing clinical datasets as well as animal models. Notably,APOE2was associated with preserved activity during aging, which also associated with lifespan. In animal models, distinct apoE isoform levels, whereAPOE2has the highest, were correlated with activity levels, while some forms of cholesterol and triglycerides were associated with apoE and activity levels. These results indicate thatAPOE2can contribute to longevity independent of AD. Preserved activity would be an early-observable feature ofAPOE2-mediated longevity, where higher levels of apoE2 and its-associated lipid metabolism might be involved.

1 January 2020 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Verified
Journal Article
Open access
PDF file
MSMitsuru Shinohara
Mitsuru Shinohara
YTYoshitaka Tashiro
Yoshitaka Tashiro
KSKaoru Suzuki
Kaoru Suzuki
AFAkio Fukumori
Akio Fukumori
GBGuojun Bu
Guojun Bu
NSNaoyuki Sato
Naoyuki Sato
Introduction Although diabetes and apolipoprotein E (apoE) are both significant risk factors for dementia, including Alzheimer's disease, it remains to be clarified how they are related to each other in contributing to the risk of dementia. Methods By reviewing the National Alzheimer's Coordinating Center (NACC) clinical records, we investigated whether diabetes affects cognitive decline depending on APOE genotype and their potential relationships with neuropathology. Results A significant interaction between diabetes and APOE genotype exists, where diabetes affected cognitive decline in APOE3 carriers and APOE2 carriers, but not APOE4 carriers. Moreover, the presence of vascular pathology was increased by diabetes in APOE3 carriers, while APOE4 carriers nearly reached plateau levels irrespective of diabetes. Discussion Diabetes accelerates cognitive decline, in part, through accelerating vascular impairment in non‐APOE ε4 carriers, but such effects are negligible in APOE4 carriers, who themselves are already vulnerable to vascular impairment.

6 July 2023 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
MSMitsuru Shinohara
Mitsuru Shinohara
GGGhupurjan Gheni
Ghupurjan Gheni
JHJunichi Hitomi
Junichi Hitomi
GBGuojun Bu
Guojun Bu
NSNaoyuki Sato
Naoyuki Sato
Background: While obesity in midlife is a risk factor for dementia, several studies suggested that obesity also protected against dementia, hence so-called obesity paradox. The current study aims to address the relationship between apolipoprotein E (APOE) genotype and obesity in dementia.Methods: Clinical and neuropathological records of the National Alzheimer’s Coordinating Center (NACC) in the USA, which longitudinally followed approximately 20 000 subjects with different cognitive statues,APOEgenotype and obesity states, were reviewed.Results: Obesity was associated with cognitive decline in early elderly cognitively normal individuals withoutAPOE4, especially those withAPOE2. Neuropathological analyses adjusted for dementia status showed thatAPOE2carriers tended to have more microinfarcts and haemorrhages due to obesity. On the other hand, obesity was associated with a lower frequency of dementia and less cognitive impairment in individuals with mild cognitive impairment or dementia. Such trends were particularly strong inAPOE4carriers. Obesity was associated with fewer Alzheimer’s pathologies in individuals with dementia.Conclusions: Obesity may accelerate cognitive decline in middle to early elderly cognitive normal individuals withoutAPOE4likely by provoking vascular impairments. On the other hand, obesity may ease cognitive impairment in both individuals with dementia and individuals at the predementia stage, especially those withAPOE4, through protecting against Alzheimer’s pathologies. These results support thatAPOEgenotype modifies the obesity paradox in dementia.

17 November 2017 in Brain
Verified
Journal Article
Open access
PDF file
MSMitsuru Shinohara
Mitsuru Shinohara
SKShunsuke Koga
Shunsuke Koga
TKTakuya Konno
Takuya Konno
JNJeremy Nix
Jeremy Nix
MSMotoko Shinohara
Motoko Shinohara
GBGuojun Bu
Guojun Bu
Accumulation of amyloid-β peptides is a dominant feature in the pathogenesis of Alzheimer’s disease; however, it is not clear how individual amyloid-β species accumulate and affect other neuropathological and clinical features in the disease. Thus, we compared the accumulation of N-terminally truncated amyloid-β and full-length amyloid-β, depending on disease stage as well as brain area, and determined how these amyloid-β species respectively correlate with clinicopathological features of Alzheimer’s disease. To this end, the amounts of amyloid-β species and other proteins related to amyloid-β metabolism or Alzheimer’s disease were quantified by enzyme-linked immunosorbent assays (ELISA) or theoretically calculated in 12 brain regions, including neocortical, limbic and subcortical areas from Alzheimer’s disease cases (n = 19), neurologically normal elderly without amyloid-β accumulation (normal ageing, n = 13), and neurologically normal elderly with cortical amyloid-β accumulation (pathological ageing, n = 15). We observed that N-terminally truncated amyloid-β42 and full-length amyloid-β42 accumulations distributed differently across disease stages and brain areas, while N-terminally truncated amyloid-β40 and full-length amyloid-β40 accumulation showed an almost identical distribution pattern. Cortical N-terminally truncated amyloid-β42 accumulation was increased in Alzheimer’s disease compared to pathological ageing, whereas cortical full-length amyloid-β42 accumulation was comparable between Alzheimer’s disease and pathological ageing. Moreover, N-terminally truncated amyloid-β42 were more likely to accumulate more in specific brain areas, especially some limbic areas, while full-length amyloid-β42 tended to accumulate more in several neocortical areas, including frontal cortices. Immunoprecipitation followed by mass spectrometry analysis showed that several N-terminally truncated amyloid-β42 species, represented by pyroglutamylated amyloid-β11-42, were enriched in these areas, consistent with ELISA results. N-terminally truncated amyloid-β42 accumulation showed significant regional association with BACE1 and neprilysin, but not PSD95 that regionally associated with full-length amyloid-β42 accumulation. Interestingly, accumulations of tau and to a greater extent apolipoprotein E (apoE, encoded by APOE) were more strongly correlated with N-terminally truncated amyloid-β42 accumulation than those of other amyloid-β species across brain areas and disease stages. Consistently, immunohistochemical staining and in vitro binding assays showed that apoE co-localized and bound more strongly with pyroglutamylated amyloid-β11-x fibrils than full-length amyloid-β fibrils. Retrospective review of clinical records showed that accumulation of N-terminally truncated amyloid-β42 in cortical areas was associated with disease onset, duration and cognitive scores. Collectively, N-terminally truncated amyloid-β42 species have spatiotemporal accumulation patterns distinct from full-length amyloid-β42, likely due to different mechanisms governing their accumulations in the brain. These truncated amyloid-β species could play critical roles in the disease by linking other clinicopathological features of Alzheimer’s disease.